Hemab appoints Keli Walbert to board and audit committee effective Sept 24, 2026

Hemab Therapeutics Holdings, Inc.

Keli Walbert elected Class I director, term expiring at 2027 annual meeting; also joins Audit Committee.
Granted option to purchase 36,000 shares at closing price on Sept 24, 2026; vests monthly over 3 years.
Annual cash compensation $40,000 (board) plus $10,000 (Audit Committee); equity grants per policy.
Vesting accelerates in full on change of control; standard indemnification agreement applies.
No family relationships or reportable transactions with company; no arrangement behind election.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Keli Walbert

Director

COAG · Hemab Therapeutics Holdings, Inc.

Effective: 2026-09-24
Filed: September 24, 2026, 4:03 PM ET

On September 24, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Hemab Therapeutics Holdings, Inc. (the “Company”), the Board elected Keli Walbert to serve as a member of the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Keli Walbert was elected as Director at Hemab Therapeutics Holdings, Inc..

Action: elected
Role: Director

Exact text from the filing

On September 24, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Hemab Therapeutics Holdings, Inc. (the “Company”), the Board elected Keli Walbert to serve as a member of the Board, effective immediately.

View on SEC.gov

Hemab Therapeutics Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-401010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.